Product and method for identifying, diagnosing and evaluating thyroid cancer

Abstract

The invention discloses a product and a method for identifying, diagnosing and evaluating thyroid cancer. In the specific embodiment of the invention, IgG in body fluid is separated, then N-carbohydrate chains on IgG are dissociated through glycosidase, and the expression quantity difference of the N-carbohydrate chains on IgG in thyroid cancer and non-cancer control (healthy and benign nodule) body fluid is compared by utilizing a mass spectrum-based analysis method. The inventor finds that compared with non-cancer control, the expression quantities of three N sugar chains (H3N5F1, H4N5F1 and H5N5F1) in plasma of a thyroid cancer patient are respectively and obviously increased, meanwhile the other N sugar chain H4N4F1 is obviously reduced. That is to say, differently expressed IgG N-carbohydrate chain can effectively distinguish thyroid cancer and non-cancer control, and the combination of H3N5F1, H4N5F1 and H5N5F1 also has the potential of early diagnosis of thyroid cancer. The method is high in sensitivity, a required blood sample is easy to obtain, the accuracy is high when the method is used for thyroid cancer differential diagnosis, and the method has important application value.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a product and method for differential diagnosis and evaluation of thyroid cancer. Background technique [0002] Thyroid cancer is the most common malignancy of the endocrine system. In recent years, its incidence has increased significantly. In my country, there are more than 190,000 new cases of thyroid cancer each year, which seriously threatens the health of our population. Thyroid cancer is mainly divided into four histological types. And more than 90% of them are papillary thyroid carcinoma (Papillary Thyroid Carcinoma, PTC). Epidemiological studies have shown that the palpation rate of thyroid nodules is about 5% in women and 1% in men. About 5-15% of the nodules will develop malignant lesions, which require timely surgery or other treatment, and the rest of the benign nodules need standardized follow-up. In addition, although the overall prognosis of differentia...

AI Technical Summary

Problems solved by technology

In addition, although the overall prognosis of PTC-based differentiated thyroid cancer is good, the proportion of lesions that obviously invade the surrounding important structures at the time of diagnosis is 6% to 13%, and the proportion of distant metastasis is 5.9% to 23%. The annual survival rate is significantly reduced (26% to 70%). When the distant metastatic lesions do not take iodine after surgery (iodine refractory), the 10-year survival rate of the patient is less than 10%

However, there is still a lack of studies evaluating whether glycosylation of thyroid cancer proteins can be used as a differential diagnosis of thyroid cancer

Images